The average one-year price target for Genmab A (NasdaqGS:GMAB) has been revised to $55.27 / share. This is a decrease of ...

An update from Genmab ( ($GMAB) ) is now available. On November 10, 2025, Genmab A/S announced a proposed private offering of $1.5 billion in ...

Genmab also launched the syndication of a new $2.0 billion senior secured term loan “B” facility, which term loan “B” facility is in addition to a $1.0 billion senior secured term loan “A” facility ...

November 6, 2025 Copenhagen, Denmark; Interim Report for the Nine Months Ended September 30, 2025HighlightsAnnouncement of Genmab’s proposed ...

In its most recent quarterly report, Genmab A/S posted strong results, with third quarter sales reaching US$1.02 billion and net income more than doubling compared to a year earlier. The company also ...

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, ...

This article first appeared on GuruFocus. Genmab AS (NASDAQ:GMAB) is set to release its Q3 2025 earnings on Nov 6, 2025. The ...

Danish biotech Genmab reported a 25% rise in its total revenue to $1.02 billion during the third quarter of 2025, ahead of ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other ...

News that Genmab would expand its footprint in Princeton broke earlier this month, when it secured an award through the state’s Emerge tax incentive program. Colliers announced March 26 it negotiated ...

Copenhagen, Denmark; January 5, 2009 - Genmab A/S (OMX: GEN) announced today that the interim survival analysis of the Phase III pivotal study investigating zalutumumab (HuMax-EGFr®) in refractory ...